Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on the proposed merger with TuHURA Biosciences, which aims to create a combined company focused on advancing a diversified late-stage oncology pipeline [1][3]. Company Overview - Kintara Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to developing novel cancer therapies for patients with unmet medical needs [10][12]. - The company's lead program is REM-001 Therapy, which targets cutaneous metastatic breast cancer (CMBC) and has shown an 80% clinical efficacy rate in previous trials [11]. Merger Details - The merger agreement is an all-stock transaction, with pre-merger Kintara equityholders expected to own approximately 2.85% of the combined company, while pre-merger TuHURA equityholders are expected to own about 97.15% [3]. - The combined entity will operate under the name "TuHURA Biosciences, Inc." and will trade on The Nasdaq Capital Market under the ticker "HURA" [3]. - The transaction is anticipated to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval from both companies [3]. TuHURA Biosciences Overview - TuHURA Biosciences is an immuno-oncology company in the Phase 3 registration stage, developing technologies to overcome resistance to cancer immunotherapy [8]. - The lead candidate, IFx-2.0, is designed to be used alongside Keytruda® for treating advanced or metastatic Merkel Cell Carcinoma [8]. Voting Information - Stockholders must vote by 11:59 p.m. Eastern Time on September 19, 2024, for their votes to count, and those eligible to vote include stockholders as of August 14, 2024 [5][6]. - Voting can be conducted via phone or internet, with specific instructions provided for different platforms [6][7].
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.